Screening of Kabasura Kudineer Chooranam Against COVID-19 Through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies
38 Pages Posted: 17 Jun 2020
Date Written: June 12, 2020
Background: COVID-19 is the infectious pandemic disease caused by the novel coronavirus. The COVID-19 is spread globally in a short span of time. It was first identified in Wuhan, China in December 2019. According to the WHO reports as on 14th April 20, 2020,as affected about 17,73,084 people and recorded 1,11,652 deaths globally. The Indian Council of Medical Research (ICMR) has recommended chemoprophylaxis with Hydroxychloroquine for the management of COVID-19. The Department of AYUSH which promotes Siddha and other Indian system of Medicine recommends the use of formulation like Nilavembu Kudineer and Kaba Sura Kudineer Chooranam (KSKC). The current work seeks to provide the scientific bases for the use of KSKC.
Method: The present work seeks to provide the evidence for the action of 74 different constituents of the KSKC formulation acting on two critical targets. That is main protease and SARS-Cov-2 RNA-dependent RNA polymerase target through molecular docking experiments. The molecular docking was done by using AutoDock Tools 1.5.6.
Result: Of the 74 compounds 50 compounds yielded docking results against COVID-19 main protease while 42 compounds yielded against SARS-cov2 RNA-dependent RNA polymerase.
Conclusion: This research has concluded that the KSKC has the lead molecules that inhibits COVID-19’s target of main protease of COVID-19 and SARSCov-2 RNA-dependent RNA polymerase.
Note: Funding: None.
Conflict of Interest: None.
Keywords: SARS-CoV-2, AYUSH, Computational model, AutoDock, In silico, Siddha
Suggested Citation: Suggested Citation